Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.

Corti G, Bartolini A, Crisafulli G, Novara L, Rospo G, Montone M, Negrino C, Mussolin B, Buscarino M, Isella C, Barault L, Siravegna G, Siena S, Marsoni S, Di Nicolantonio F, Medico E, Bardelli A.

Clin Colorectal Cancer. 2019 Jun;18(2):91-101.e3. doi: 10.1016/j.clcc.2019.02.008. Epub 2019 Mar 7.

PMID:
30981604
2.

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.

Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F.

Eur J Cancer. 2019 Jan;107:164-174. doi: 10.1016/j.ejca.2018.11.016. Epub 2018 Dec 19.

PMID:
30579113
3.

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F.

Ann Oncol. 2018 Aug 1;29(8):1800-1806. doi: 10.1093/annonc/mdy197.

PMID:
29860358
4.

Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor.

Fadda A, Gentilini D, Moi L, Barault L, Leoni VP, Sulas P, Zorcolo L, Restivo A, Cabras F, Fortunato F, Zavattari C, Varesco L, Gismondi V, De Miglio MR, Scanu AM, Colombi F, Lombardi P, Sarotto I, Loi E, Leone F, Giordano S, Di Nicolantonio F, Columbano A, Zavattari P.

Int J Cancer. 2018 Aug 15;143(4):907-920. doi: 10.1002/ijc.31380. Epub 2018 Apr 6.

PMID:
29542109
5.

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A.

Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29.

PMID:
29186113
6.

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.

Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomatà C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A, Sartore-Bianchi A, Di Nicolantonio F.

Gut. 2018 Nov;67(11):1995-2005. doi: 10.1136/gutjnl-2016-313372. Epub 2017 Oct 5.

7.

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S.

Eur J Cancer. 2017 Jan;71:43-50. doi: 10.1016/j.ejca.2016.10.032. Epub 2016 Dec 18.

8.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F.

Cancer Discov. 2016 Sep;6(9):963-71. doi: 10.1158/2159-8290.CD-16-0297. Epub 2016 Jun 20.

9.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F.

Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.

10.

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.

Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A, Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S.

Ann Oncol. 2016 Jun;27(6):1062-7. doi: 10.1093/annonc/mdw071. Epub 2016 Feb 24.

PMID:
26916096
11.

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F.

Ann Oncol. 2015 Sep;26(9):1994-9. doi: 10.1093/annonc/mdv272. Epub 2015 Jun 25.

12.

Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer.

Barrow TM, Barault L, Ellsworth RE, Harris HR, Binder AM, Valente AL, Shriver CD, Michels KB.

Int J Cancer. 2015 Aug 1;137(3):537-47. doi: 10.1002/ijc.29419. Epub 2015 Jan 21.

13.

BRAF V600E is a determinant of sensitivity to proteasome inhibitors.

Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F.

Mol Cancer Ther. 2013 Dec;12(12):2950-61. doi: 10.1158/1535-7163.MCT-13-0243. Epub 2013 Oct 9.

14.

The prevalence of loss of imprinting of H19 and IGF2 at birth.

Rancourt RC, Harris HR, Barault L, Michels KB.

FASEB J. 2013 Aug;27(8):3335-43. doi: 10.1096/fj.12-225284. Epub 2013 Apr 25.

15.

Leukocyte DNA as surrogate for the evaluation of imprinted Loci methylation in mammary tissue DNA.

Barault L, Ellsworth RE, Harris HR, Valente AL, Shriver CD, Michels KB.

PLoS One. 2013;8(2):e55896. doi: 10.1371/journal.pone.0055896. Epub 2013 Feb 7.

16.

DNA methylation of stress-related genes and LINE-1 repetitive elements across the healthy human placenta.

Non AL, Binder AM, Barault L, Rancourt RC, Kubzansky LD, Michels KB.

Placenta. 2012 Mar;33(3):183-7. doi: 10.1016/j.placenta.2011.12.013. Epub 2012 Jan 4.

17.

Birthweight, maternal weight trajectories and global DNA methylation of LINE-1 repetitive elements.

Michels KB, Harris HR, Barault L.

PLoS One. 2011;6(9):e25254. doi: 10.1371/journal.pone.0025254. Epub 2011 Sep 28.

18.

Immunogenic death of colon cancer cells treated with oxaliplatin.

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G.

Oncogene. 2010 Jan 28;29(4):482-91. doi: 10.1038/onc.2009.356. Epub 2009 Nov 2.

PMID:
19881547
19.

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F.

Cancer Res. 2008 Oct 15;68(20):8541-6. doi: 10.1158/0008-5472.CAN-08-1171.

20.

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lièvre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, Piard F.

Int J Cancer. 2008 May 15;122(10):2255-9. doi: 10.1002/ijc.23388.

Supplemental Content

Loading ...
Support Center